These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9708399)

  • 1. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.
    Mitsuyasu RT; Skolnik PR; Cohen SR; Conway B; Gill MJ; Jensen PC; Pulvirenti JJ; Slater LN; Schooley RT; Thompson MA; Torres RA; Tsoukas CM
    AIDS; 1998 Jul; 12(11):F103-9. PubMed ID: 9708399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
    AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
    Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
    Kline MW; Brundage RC; Fletcher CV; Schwarzwald H; Calles NR; Buss NE; Snell P; DeLora P; Eason M; Jorga K; Craig C; Duff F
    Pediatr Infect Dis J; 2001 Jul; 20(7):666-71. PubMed ID: 11465838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.
    Moyle G; Pozniak A; Opravil M; Clumeck N; DelFraissy JF; Johnson M; Pelgrom J; Reynes J; Vittecoq D; DeLora P; Salgo M; Duff F
    J Acquir Immune Defic Syndr; 2000 Feb; 23(2):128-37. PubMed ID: 10737427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
    Katlama C; Pellegrin JL; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs JM; Delfraissy JF
    HIV Med; 2001 Jan; 2(1):20-6. PubMed ID: 11737372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP; Plosker GL
    Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
    Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
    J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
    Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
    Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection.
    Perry CM; Noble S
    Drugs; 1998 Mar; 55(3):461-86. PubMed ID: 9530549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.
    Smith D; Hales G; Roth N; Law M; Ray J; Druett J; Mitchell J; Mills G; Doong N; Franklin R;
    HIV Clin Trials; 2001; 2(2):97-107. PubMed ID: 11590517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study.
    Sension MG; Farthing C; Shaffer AG; Graham E; Siemon-Hryczyk P; Pilson RS
    AIDS Patient Care STDS; 2001 Mar; 15(3):129-36. PubMed ID: 11313025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
    Montaner JS; Schutz M; Schwartz R; Jayaweera DT; Burnside AF; Walmsley S; Saag MS
    MedGenMed; 2006 May; 8(2):36. PubMed ID: 16926775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
    Gisolf EH; Jurriaans S; Pelgrom J; van Wanzeele F; van der Ende ME; Brinkman K; Borst MJ; de Wolf F; Japour AJ; Danner SA
    AIDS; 2000 Mar; 14(4):405-13. PubMed ID: 10770543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
    Gisolf EH; Enting RH; Jurriaans S; de Wolf F; van der Ende ME; Hoetelmans RM; Portegies P; Danner SA
    AIDS; 2000 Jul; 14(11):1583-9. PubMed ID: 10983645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.